lactobacillus gasseri
PreclinicalSmall molecule
lactobacillus gasseri is one of 8 small molecule programs targeting Vulvovaginal Candidiasis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Vulvovaginal Candidiasis
#DrugCompanyPhaseTrials
1Lotrimin
BayerApproved
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Nizoral
WWim Janssens
Approved
Terazol 3
WWim Janssens
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
lactobacillus gasseri
MMedical University of Vienna
Preclinical
Oteseconazole (VT-1161)
MMycovia Pharmaceuticals Inc.
Preclinical
Azole Antifungal
AAssiut University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for lactobacillus gasseri. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMedical University of Vienna